Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
153kB
[img] Other (Supporting Information)
45kB

Item Type:Article
Title:Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
Creators Name:Winkelmann, N. and Schwarz, M. and Hildebrandt, B. and Henke, O. and Bullinger, L. and Na, I.K. and Stintzing, S. and le Coutre, P.
Abstract:In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety-one patients with CML and 76 controls were included and in total 4 (4.4%) secondary malignancies were found in patients and 8 (10.5%) in controls. The risk for secondary malignancies was not significantly elevated for CML patients (p = 0.141). Two (2.2%) CML patients developed colorectal cancer compared to 4 (5.3%) in the reference group. A higher risk for CML patients for colorectal cancer could not be found (p = 0.414).
Keywords:Chronic Myeloid Leukemia, Colorectal Cancer, Secondary Malignancy
Source:eJHaem: The Official Journal of the British Society for Haematology
ISSN:2688-6146
Publisher:Wiley
Volume:3
Number:3
Page Range:949-953
Date:August 2022
Official Publication:https://doi.org/10.1002/jha2.502
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library